Streetbeat News

Partnerships

BABA

INTC

TSLA

TSM

XPEV

Cryptocurrencies like Bitcoin, Ethereum, and Dogecoin are experiencing a dip amid high selling pressure, with analysts suggesting Bitcoin won't see highs unless it breaks $69K. Tesla is shifting investor focus to its energy business amid an auto slowdown. ARK's Bitcoin ETF sees a record outflow, and Intel, XPeng stocks move lower. Alibaba announces a $4.8B stock repurchase, and TSMC suspends chip production due to a tremor in Taiwan. Tesla faces criticism and potential fourth session of losses, while Geely's Zeekr revives IPO plans.

Portfolio Pulse from Akanksha Bakshi

April 03, 2024 | 12:50 pm

ABIO

HSDT

LGVC

Shares of ARCA Biopharma (ABIO) surged 165% following a merger announcement with Oruka Therapeutics. LAMF Global Ventures Corp. I (LGVC) shares jumped 193% after shareholders approved a business combination with Nuvo Group Ltd. Helius Medical Technologies, Inc. (HSDT) saw a 50% increase in its shares after announcing a partnership with Lovell Government Services to expand the reach of its PoNS Therapy.

Portfolio Pulse from ryanfaloona@benzinga.com

April 03, 2024 | 12:41 pm

ASML

INTC

TSM

Intel Corporation (NASDAQ:INTC) reported a $7 billion operating loss for its foundry business in 2023, a significant increase from the previous year's $5.2 billion loss. Revenue for the unit dropped 31% to $18.9 billion. Shares fell 4.3% following the disclosure. CEO Pat Gelsinger anticipates the worst losses in 2024 but aims for a break-even by 2027. The company's strategic missteps included not adopting EUV machines from ASML (ASML) earlier. Intel plans to reduce outsourcing to companies like TSMC and invest $100 billion in U.S. chip factories.

Portfolio Pulse from Benzinga Neuro

April 03, 2024 | 12:40 pm

VRNT

Verint has expanded its partnership with Webex by Cisco, integrating Verint Open Platform's Unified Data Hub into the Webex App Hub. This integration aims to enhance customer experience (CX) automation through the Webex Contact Center.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 12:37 pm

GNPX

Genprex is expanding its clinical trial sites for the Acclaim-3 clinical study, which tests Reqorsa Therapy in combination with Tecentriq for treating small cell lung cancer. This expansion is in collaboration with a large network of community-based oncology practices. The Acclaim-3 study has received support from the FDA in the form of Orphan Drug and Fast Track Designations.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 12:32 pm

MTEK

Maris-Tech announced receiving a new order worth $415,800 from an existing defense industry customer, indicating continued business and potential growth in its defense sector engagements.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 12:12 pm

ICAD

iCAD, Inc. has announced a partnership with RAD-AID to enhance breast cancer detection in underserved regions through the use of artificial intelligence (AI). This collaboration aims to leverage iCAD's AI technology to improve early detection and treatment of breast cancer, potentially saving lives in areas with limited access to advanced medical technologies.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 12:06 pm

FXZ

SLX

United States Steel Corporation (NYSE:X) has signed a definitive agreement with CarbonFree to implement SkyCycle technology at its Gary Works Blast Furnaces, aiming to capture and mineralize 50,000 metric tons of CO2 annually. This initiative supports U.S. Steel's environmental goals, including a 20% reduction in greenhouse gas intensity by 2030 and net-zero emissions by 2050. The construction of the SkyCycle plant is expected to begin in summer 2024, with operations starting in 2026. The project, a first in North America, also offers investment opportunities through VanEck Steel ETF (NYSE:SLX) and First Trust Materials AlphaDEX Fund (NYSE:FXZ).

Portfolio Pulse from Nabaparna Bhattacharya

April 03, 2024 | 12:01 pm

HSDT

Helius Medical Technologies' stock is trading higher following the announcement of a partnership with Lovell Government Services to distribute its PoNS device to federal healthcare systems.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 11:36 am

SNGX

Soligenix has reached an agreement with the European Medicines Agency (EMA) on the design of a second confirmatory placebo-controlled trial for HyBryte, a treatment under development.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 11:31 am